Aadi Bioscience

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aadi Bioscience reports robust FYARRO sales and optimistic outlook for 2023

Aadi Bioscience showcased strong sales performance and financial stability in 2022.
The company's strengths lie in successful product launches, collaborations, and trial outcomes.
Challenges include managing expenses and meeting expectations for future data releases.
Excitement for 2023 signals potential growth opportunities and continued success.

Aadi Bioscience reports revenue growth and clinical progress in Q1

Aadi Bioscience demonstrated strong performance with revenue growth, progress in clinical trials, and a solid financial position.
The company's strengths lie in its product pipeline, clinical trial advancements, and financial stability, positioning it well for future growth.
While facing challenges in sales growth, trial timelines, and global expansion, Aadi Bioscience has opportunities to diversify its portfolio and explore new markets.

Aadi Bioscience reports robust Q2 earnings and expands pipeline offerings

Aadi Bioscience's Q2 performance reflects strong revenue growth, promising pipeline developments, and a solid financial position, positioning the company for future success.
While facing challenges in managing expenses and clinical trials, the company has opportunities to leverage its momentum, expand its market reach, and drive innovation.
Investors should take note of Aadi Bioscience's strategic advancements and financial stability, signaling potential for growth and value creation in the biopharmaceutical sector.

Aadi Bioscience reports solid Q3 results, advances cancer treatment innovations

Aadi Bioscience's Q3 performance reflects financial stability, increased expenses, and progress in advancing nab-Sirolimus for mutated cancers.
The company's strengths lie in new leadership, innovative treatment potential, and a tumor-agnostic trial approach, positioning it for future success.
Challenges include addressing analyst inquiries, meeting trial timeline goals, and managing financial resources effectively amidst growth and innovation.
Opportunities abound in potentially transforming cancer treatment, showcasing advancements, and expanding the pipeline with innovative approaches.

Aadi Bioscience reports robust sales growth and advances in cancer trials

Aadi Bioscience's strong financial performance in 2023, driven by robust FYARRO sales and a focus on operational efficiency, sets a solid foundation for future growth and innovation.
While challenges exist in managing R&D expenses and trial timelines, the company's strategic measures and positive outlook position them well to capitalize on opportunities in expanding their therapeutic reach.
With ongoing trials showing promising results and a proactive approach to presenting new data, Aadi Bioscience remains committed to advancing novel treatments and delivering value to patients and investors alike.

Aadi Bioscience reports steady Q1 sales and optimistic trial progress

Aadi Bioscience's Q1 performance reflects steady sales and strong cash position supporting future operations.
The company's focus on advancing clinical trials and strategic program alignment positions it for future growth.
Challenges in sales and collaboration changes present areas for ongoing monitoring and strategic adjustments.

Aadi Bioscience reports robust Q2 sales and advances in nab-Sirolimus trials

Aadi Bioscience's Q2 performance reflects steady growth in FYARRO sales and progress in nab-Sirolimus trials for various tumor types.
Despite challenges in meeting expectations and market dynamics, the company's strong financial position and confidence in its products are notable strengths.
With a cash runway into Q4 2025 and a promising pipeline, Aadi is poised for growth and success in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.

Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates

FYARRO® sales of $7.2 million for Q3 2024, reflecting 21% year over year sales growth Aadi continues to focus on FYARRO commercial business and comprehensive strategic review to maximize shareholder value LOS ANGELES , Nov. 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand and a nearly 90 percent reorder rate – all reinforcing the clinical value of FYARRO for patients with advanced malignant PEComa," said Dave Lennon, President and CEO of Aadi Bioscience.

Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update

LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

PRECISION1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted Aadi will focus on FYARRO® commercial business for its approved indication, PEComa, and conduct a comprehensive strategic review to maximize shareholder value To further preserve cash position, Aadi will adjust ongoing Phase 2 trials and reduce R&D headcount by 80%, thereby extending cash runway into at least 2H 2026 LOS ANGELES , Aug. 20, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study.

Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q2 2024 Earnings Conference Call August 7, 2024 8:30 AM ET Company Participants David Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience Inc. Second Quarter 2024 Earnings Call.

Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.67 per share a year ago.

Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates

FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES , Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and existing accounts, including from major oncology centers.

Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

Company to Host Conference Call and Webcast on August 7, 2024 LOS ANGELES , July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update

Applied Optoelectronics

Southern California Bancorp

One of many stock market indexes used to measure performance, the Russell 2000 is composed of 2,000 small-cap companies that make up the bottom two-thirds of the Russell 3000 index. The reason is that the top 1,000 stocks in the Russell 3000 make up 93% of the index's market cap, so focusing on the lower 2,000 allows analysts and investors to judge the movement of the small-cap market more accurately.

3 Russell 2000 Stocks to Sell in July Before They Crash & Burn

LOS ANGELES , May 29, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, announced today participation in the Jefferies Healthcare Conference, taking place June 5-6, 2024, in New York. Dave Lennon, Ph.D.

Aadi Bioscience to Participate in the Jefferies Healthcare Conference

nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model Data support further clinical exploration of nab-sirolimus as a single agent or in combination LOS ANGELES , May 23, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced new nonclinical data demonstrating the significantly higher intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity of nab-sirolimus compared to intravenous and oral mTOR inhibitors in a xenograft model. These data will be available as an abstract and published in the Journal of Clinical Oncology supplement to coincide with the American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4, 2024.

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Dave Lennon - President and Chief Executive Officer Scott Giacobello - Chief Financial Officer, Investor Relations and Corporate Communications Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Joseph Catanzaro - Piper Sandler Tara Bancroft - TD Cowen Ahu Demir - Ladenburg Thalmann Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience First Quarter 2024 Earnings Conference Call.

Aadi Bioscience, Inc. (AADI) Q1 2024 Earnings Call Transcript

Fully enrolled registration-intended PRECISION1 trial;  two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES , May 8, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "I'm pleased to announce that PRECISION1 is now fully enrolled across a broad array of tumor types and our promising development plan continues to gain momentum.

Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update

Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES , May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates. Conference Call Information  Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at  aadibio.com.

Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update

Data further support clinical exploration of nab-sirolimus in combination with endocrine therapy for hormone-driven cancers, as is currently being investigated for patients with endometrioid-type endometrial cancer in a Phase 2 trial Data highlight potential for synergy to enhance anti-cancer effects and overcome resistance in non-small cell lung cancer LOS ANGELES , April 9, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, taking place April 5-10, 2024.

Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting

Here is how Aadi Bioscience, Inc. (AADI) and Amplifon S.p.A. (AMFPF) have performed compared to their sector so far this year.

Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year?

Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year?

Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers LOS ANGELES , March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status.

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.60 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.52 per share a year ago.

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates

FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations  on track to complete enrollment by May; two-thirds interim analysis planned for Q3 2024 Phase 2 trials in Endometrial Cancer and Neuroendocrine Tumors (NETs) actively enrolling patients Conference call to be held today at 8:30 am EDT LOS ANGELES , March 13, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and highlighted recent corporate progress. "With strong execution against our commercial and development goals, 2023 was a year of progress and momentum for Aadi," said Dave Lennon, President and CEO of Aadi Bioscience.

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update

Company to Host Conference Call and Webcast on March 13, 2024 LOS ANGELES , March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024 at 8:30 am ET (5:30 am PT) to report fourth quarter and full-year 2023 financial results and provide recent corporate updates. Conference Call Information  Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at  aadibio.com.

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update

LOS ANGELES , March 5, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, today announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA. AACR poster presentation details are below: Title: " Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines " Session Title: Reversal of Drug Resistance 2 Location: Poster Section 25, Board Number 6 Abstract Number: 7196 Date/Time: Wednesday Apr 10, 2024, 9:00 AM - 12:30 PM Presenting Author: Shihe Hou, PhD Title: "Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors" Session Title: Targeting Kinase and ERK Pathways Location: Poster Section 46, Board Number 3 Abstract Number: 6486 Date/Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PM Presenting Author: Shihe Hou, PhD More information can be found on the AACR meeting website.

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses Demonstrated 40 months median duration of response and median survival >53 months Historically, median survival has ranged from 16 to 29 months in the setting of metastatic/unresectable malignant PEComa1,2 LOS ANGELES , March 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, announced today that long-term efficacy and safety results from its completed Phase 2 registrational AMPECT study of nab-sirolimus in malignant PEComa were published in the Journal of Clinical Oncology (JCO). The manuscript, "A Phase 2 Trial of nab-Sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-term Efficacy and Safety Update," authored by Andrew J.

Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa

LOS ANGELES , Feb. 26, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, announced today its presentation at the TD Cowen 44th Annual Healthcare Conference, taking place March 4-6, 2024, in Boston. Dave Lennon, Ph.D.

News for Aadi Bioscience Stock (AADI)